| Expression pattern: |
UP |
| Associated gene: |
Bcl-2, Bax |
| Associated microRNA: |
miR-195 |
| Biological function: |
Promotes NSCLC progression by enhancing proliferation, migration and invasion and inhibiting apoptosis. |
| Molecular mechanism: |
Acts as a competing endogenous RNA (ceRNA) to sponge miR-195, thereby relieving repression of Bcl-2 and affecting apoptosis-related proteins. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Survival Analysis; Transfection; MTT; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; Luciferase Reporter Assay; Bioinformatics Analysis |
| Clinical significance: |
High circVANGL1 expression was associated with larger tumor size, advanced TNM stage, and unfavorable overall survival in NSCLC patients. |
| Description: |
circVANGL1 is up-regulated in NSCLC tissues/cell lines and promotes malignant phenotypes (proliferation, migration, invasion) while inhibiting apoptosis. Mechanistically, it functions as a ceRNA that sponges miR-195 to increase Bcl-2 expression, and high circVANGL1 correlates with poorer overall survival. |
| Confidence score: |
0.7113 |